Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

735 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Monoclonal antibody therapy of kidney cancer.
Oosterwijk E, Brouwers A, Boerman OC, Larson SM, Old LJ, Mulders P, Divgi CR. Oosterwijk E, et al. Among authors: old lj. Cancer Treat Res. 2003;116:199-212. doi: 10.1007/978-1-4615-0451-1_12. Cancer Treat Res. 2003. PMID: 14650834 Review. No abstract available.
Antibody therapy in renal cell carcinoma.
Oosterwijk E, Boerman OC, Oyen WJ, Old LJ, Mulders PF. Oosterwijk E, et al. Among authors: old lj. World J Urol. 2008 Apr;26(2):141-6. doi: 10.1007/s00345-008-0236-5. Epub 2008 Feb 1. World J Urol. 2008. PMID: 18239922 Free PMC article. Review.
Monoclonal antibody-based therapy for renal cell carcinoma.
Oosterwijk E, Divgi CR, Brouwers A, Boerman OC, Larson SM, Mulders P, Old LJ. Oosterwijk E, et al. Among authors: old lj. Urol Clin North Am. 2003 Aug;30(3):623-31. doi: 10.1016/s0094-0143(03)00028-4. Urol Clin North Am. 2003. PMID: 12953760 Review.
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, Larson SM, Old LJ. Konner JA, et al. Among authors: old lj. Clin Cancer Res. 2010 Nov 1;16(21):5288-95. doi: 10.1158/1078-0432.CCR-10-0700. Epub 2010 Sep 20. Clin Cancer Res. 2010. PMID: 20855460 Clinical Trial.
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
Bauer S, Oosterwijk-Wakka JC, Adrian N, Oosterwijk E, Fischer E, Wüest T, Stenner F, Perani A, Cohen L, Knuth A, Divgi C, Jäger D, Scott AM, Ritter G, Old LJ, Renner C. Bauer S, et al. Among authors: old lj. Int J Cancer. 2009 Jul 1;125(1):115-23. doi: 10.1002/ijc.24359. Int J Cancer. 2009. PMID: 19384924
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.
Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P. Divgi CR, et al. Among authors: old lj. Lancet Oncol. 2007 Apr;8(4):304-10. doi: 10.1016/S1470-2045(07)70044-X. Lancet Oncol. 2007. PMID: 17395103 Clinical Trial.
735 results